Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-

Innovators are finding new ways of targeting E3 ligases and DUBs in liver diseases and cancer: BioCentury’s survey of the 2023 translational literature

BioCentury’s roundup of translational innovations

Gilead retains ownership of nearly half of Tizona’s equity via $300M investment in 2020, but won’t take full control of anti-HLA-G antibody

Inovio spin-out combining parent company’s plasmid delivery system with neoantigen technology from David Weiner’s lab at Wistar